Press Releases Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
6.51 ^USD	-2.11%		+7.60%	+7.25%

06/05	Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating	MT
03/05	Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amneal Reports First Quarter 2024 Financial Results	06/05	AQ
Amneal Pharmaceuticals : First Quarter 2024 Earnings Presentation	03/05	PU
Amneal: Q1 Earnings Snapshot	03/05	AQ
Amneal Reports First Quarter 2024 Financial Results	03/05	BU
California is joining with a New Jersey company to buy a generic opioid overdose reversal drug	29/04	AQ
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose	24/04	BU
Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable Medicine	17/04	AQ
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine	16/04	BU
Amneal to Report First Quarter 2024 Results on May 3, 2024	10/04	BU
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024	29/03	BU
Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful	28/03	AQ
Amneal Pharmaceuticals : LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful.	28/03	PU
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension	26/03	BU
Amneal Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	04/03	AQ
Amneal: Q4 Earnings Snapshot	01/03	AQ
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results	01/03	BU
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203	27/02	BU
Amneal to Participate at Upcoming Investor Conference	13/02	BU
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application	09/02	AQ
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024	01/02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Press Releases

Filters